Androgen-independent effects of Serenoa repens extract (Prostasan®) on prostatic epithelial cell proliferation and inflammation
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Androgen-independent effects of Serenoa repens extract (Prostasan®) on prostatic epithelial cell proliferation and inflammation. / Iglesias-Gato, Diego; Carsten, Tober; Vesterlund, Mattias; Pousette, Ake; Schoop, Roland; Norstedt, Gunnar.
In: Phytotherapy Research, Vol. 26, No. 2, 02.2012, p. 259-64.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Androgen-independent effects of Serenoa repens extract (Prostasan®) on prostatic epithelial cell proliferation and inflammation
AU - Iglesias-Gato, Diego
AU - Carsten, Tober
AU - Vesterlund, Mattias
AU - Pousette, Ake
AU - Schoop, Roland
AU - Norstedt, Gunnar
N1 - Copyright © 2011 John Wiley & Sons, Ltd.
PY - 2012/2
Y1 - 2012/2
N2 - Extracts from Serenoa repens are widely used for the treatment of benign prostatic hyperplasia (BPH) and traditionally for prostatitis. In the present study we evaluated the biological effects of Serenoa repens extract (Prostasan®) on prostate cells beyond its known antiandrogenic actions. Prostasan® inhibited epidermal growth factor (EGF) and lipopolysaccharide (LPS) induced proliferation of the prostatic epithelial, androgen independent cell line PC-3. At effective concentrations of 50 µg/mL, Prostasan® partly displaced EGF from EGF receptor (EGFR) but fully blocked EGF-induced cell proliferation of PC-3 cells. Similarly, Prostasan® inhibited LPS-induced proliferation of PC-3 cells without affecting LPS activation of the NFĸB pathway via toll-like receptor-4 (TLR-4). Additionally, Prostasan® reduced the constitutive secretion of monocyte chemotactic protein-1 (MCP-1), the LPS-induced secretion of IL-12 and inhibited MCP-1 and granulocyte-macrophage colony-stimulating factor (GM-CSF) production in the presence of LPS on PC-3 cells. Taken together, our results suggest that S. repens extracts, in addition to other reported effects on BPH development and prostatitis, inhibits EGF-dependent growth and proinflammatory responses of the prostate epithelial cells.
AB - Extracts from Serenoa repens are widely used for the treatment of benign prostatic hyperplasia (BPH) and traditionally for prostatitis. In the present study we evaluated the biological effects of Serenoa repens extract (Prostasan®) on prostate cells beyond its known antiandrogenic actions. Prostasan® inhibited epidermal growth factor (EGF) and lipopolysaccharide (LPS) induced proliferation of the prostatic epithelial, androgen independent cell line PC-3. At effective concentrations of 50 µg/mL, Prostasan® partly displaced EGF from EGF receptor (EGFR) but fully blocked EGF-induced cell proliferation of PC-3 cells. Similarly, Prostasan® inhibited LPS-induced proliferation of PC-3 cells without affecting LPS activation of the NFĸB pathway via toll-like receptor-4 (TLR-4). Additionally, Prostasan® reduced the constitutive secretion of monocyte chemotactic protein-1 (MCP-1), the LPS-induced secretion of IL-12 and inhibited MCP-1 and granulocyte-macrophage colony-stimulating factor (GM-CSF) production in the presence of LPS on PC-3 cells. Taken together, our results suggest that S. repens extracts, in addition to other reported effects on BPH development and prostatitis, inhibits EGF-dependent growth and proinflammatory responses of the prostate epithelial cells.
KW - Cell Line
KW - Cell Proliferation
KW - Cytokines
KW - Epidermal Growth Factor
KW - Epithelial Cells
KW - Humans
KW - Inflammation
KW - Lipopolysaccharides
KW - Male
KW - Plant Extracts
KW - Prostate
KW - Receptor, Epidermal Growth Factor
KW - Serenoa
KW - Journal Article
U2 - 10.1002/ptr.3537
DO - 10.1002/ptr.3537
M3 - Journal article
C2 - 21656602
VL - 26
SP - 259
EP - 264
JO - Phytotherapy Research
JF - Phytotherapy Research
SN - 0951-418X
IS - 2
ER -
ID: 167178875